$36.02
1.223.51%
At Close: -
$36.02
00.00%
After Hours: Jul 3, 1:00 PM EDT
15 minutes delayed
Immunocore Hldgs
IMCRNASDAQ
Immunocore Hldgs (NASDAQ:IMCR) Stock, Analyst Ratings, Price Targets, Predictions
Immunocore Holdings PLC has a consensus price target of $76.94, established from looking at the 59 latest analyst ratings. The last 3 analyst ratings were released from HC Wainwright & Co., Needham, and HC Wainwright & Co. on June 5, 2024, June 3, 2024, and May 30, 2024. With an average price target of $93.67 between HC Wainwright & Co., Needham, and HC Wainwright & Co., there's an implied 160.04% upside for Immunocore Holdings PLC from these 3 analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
Needham
Mizuho
Canaccord Genuity
Leerink Partners
1calculated from analyst ratings
Analyst Ratings for Immunocore Hldgs
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 06/05/2024 | Buy Now | 177.62% | HC Wainwright & Co. | Patrick Trucchio | $100 → $100 | Reiterates | Buy → Buy | Get Alert |
| 06/03/2024 | Buy Now | 124.88% | Needham | Gil Blum | $81 → $81 | Reiterates | Buy → Buy | Get Alert |
| 05/30/2024 | Buy Now | 177.62% | HC Wainwright & Co. | Patrick Trucchio | $100 → $100 | Reiterates | Buy → Buy | Get Alert |
| 05/29/2024 | Buy Now | 124.88% | Needham | Gil Blum | → $81 | Reiterates | Buy → Buy | Get Alert |
| 05/24/2024 | Buy Now | 177.62% | HC Wainwright & Co. | Patrick Trucchio | → $100 | Reiterates | Buy → Buy | Get Alert |
| 05/24/2024 | Buy Now | 124.88% | Needham | Gil Blum | → $81 | Reiterates | Buy → Buy | Get Alert |
| 05/13/2024 | Buy Now | 144.31% | Mizuho | Graig Suvannavejh | $90 → $88 | Maintains | Buy | Get Alert |
| 05/09/2024 | Buy Now | 86.01% | Canaccord Genuity | Bill Maughan | $63 → $67 | Maintains | Hold | Get Alert |
| 05/09/2024 | Buy Now | 177.62% | HC Wainwright & Co. | Patrick Trucchio | $90 → $100 | Maintains | Buy | Get Alert |
| 05/09/2024 | Buy Now | 124.88% | Needham | Gil Blum | → $81 | Reiterates | Buy → Buy | Get Alert |
| 04/29/2024 | Buy Now | 105.44% | Leerink Partners | Jonathan Chang | → $74 | Initiates | → Outperform | Get Alert |
| 04/23/2024 | Buy Now | 155.41% | Guggenheim | Michael Schmidt | → $92 | Reiterates | Buy → Buy | Get Alert |
| 04/11/2024 | Buy Now | 124.88% | Needham | Gil Blum | → $81 | Reiterates | Buy → Buy | Get Alert |
| 03/20/2024 | Buy Now | 94.34% | JP Morgan | Jessica Fye | $60 → $70 | Maintains | Overweight | Get Alert |
| 03/06/2024 | Buy Now | 149.86% | HC Wainwright & Co. | Patrick Trucchio | → $90 | Reiterates | Buy → Buy | Get Alert |
| 03/05/2024 | Buy Now | 149.86% | Mizuho | Graig Suvannavejh | $86 → $90 | Maintains | Buy | Get Alert |
| 02/29/2024 | Buy Now | 141.53% | Oppenheimer | Justin Kim | $85 → $87 | Reiterates | Outperform → Outperform | Get Alert |
| 02/29/2024 | Buy Now | 74.9% | Canaccord Genuity | Bill Maughan | $60 → $63 | Maintains | Hold | Get Alert |
| 02/29/2024 | Buy Now | 124.88% | Needham | Gil Blum | → $81 | Reiterates | Buy → Buy | Get Alert |
| 02/16/2024 | Buy Now | 138.76% | Mizuho | Graig Suvannavejh | $72 → $86 | Maintains | Buy | Get Alert |
| 11/20/2023 | Buy Now | 66.57% | JP Morgan | Jessica Fye | → $60 | Reinstates | → Overweight | Get Alert |
| 11/02/2023 | Buy Now | — | Cantor Fitzgerald | Eric Schmidt | — | Initiates | → Overweight | Get Alert |
| 10/31/2023 | Buy Now | 133.2% | Baird | Jack Allen | → $84 | Initiates | → Outperform | Get Alert |
| 09/21/2023 | Buy Now | 135.98% | Oppenheimer | Justin Kim | $75 → $85 | Maintains | Outperform | Get Alert |
| 09/13/2023 | Buy Now | 108.22% | Needham | Gil Blum | → $75 | Initiates | → Buy | Get Alert |
| 08/23/2023 | Buy Now | 149.86% | HC Wainwright & Co. | Patrick Trucchio | → $90 | Reiterates | Buy → Buy | Get Alert |
| 08/16/2023 | Buy Now | 133.2% | Capital One | Naureen Quibria | → $84 | Initiates | → Overweight | Get Alert |
| 08/11/2023 | Buy Now | 152.64% | BTIG | Justin Zelin | $85 → $91 | Maintains | Buy | Get Alert |
| 08/11/2023 | Buy Now | 108.22% | Oppenheimer | Justin Kim | $72 → $75 | Maintains | Outperform | Get Alert |
| 08/11/2023 | Buy Now | 149.86% | HC Wainwright & Co. | Patrick Trucchio | → $90 | Reiterates | Buy → Buy | Get Alert |
| 08/01/2023 | Buy Now | 119.32% | Morgan Stanley | Andrew Galler | $79 → $79 | Reiterates | Overweight → Overweight | Get Alert |
| 07/31/2023 | Buy Now | 119.32% | Morgan Stanley | Andrew Galler | $79 → $79 | Reiterates | Overweight → Overweight | Get Alert |
| 07/24/2023 | Buy Now | 119.32% | Morgan Stanley | Andrew Galler | $79 → $79 | Reiterates | Overweight → Overweight | Get Alert |
| 07/17/2023 | Buy Now | 119.32% | Morgan Stanley | Andrew Galler | $79 → $79 | Reiterates | Overweight → Overweight | Get Alert |
| 07/17/2023 | Buy Now | 86.01% | Canaccord Genuity | Bill Maughan | → $67 | Initiates | → Hold | Get Alert |
| 07/11/2023 | Buy Now | 119.32% | Morgan Stanley | Andrew Galler | $79 → $79 | Reiterates | Overweight → Overweight | Get Alert |
| 06/26/2023 | Buy Now | 119.32% | Morgan Stanley | Andrew Galler | $79 → $79 | Reiterates | Overweight → Overweight | Get Alert |
| 06/20/2023 | Buy Now | 119.32% | Goldman Sachs | Rajan Sharma | → $79 | Reiterates | → Overweight | Get Alert |
| 06/12/2023 | Buy Now | 119.32% | Morgan Stanley | Andrew Galler | → $79 | Reiterates | → Overweight | Get Alert |
| 05/12/2023 | Buy Now | 149.86% | HC Wainwright & Co. | Patrick Trucchio | → $90 | Reiterates | Buy → Buy | Get Alert |
| 05/11/2023 | Buy Now | 105.44% | Mizuho | Graig Suvannavejh | $70 → $74 | Maintains | Buy | Get Alert |
| 05/09/2023 | Buy Now | 149.86% | HC Wainwright & Co. | Patrick Trucchio | → $90 | Reiterates | → Buy | Get Alert |
| 04/19/2023 | Buy Now | 149.86% | HC Wainwright & Co. | Patrick Trucchio | → $90 | Reiterates | → Buy | Get Alert |
| 03/31/2023 | Buy Now | 94.34% | Mizuho | Graig Suvannavejh | → $70 | Initiates | → Buy | Get Alert |
| 03/30/2023 | Buy Now | 135.98% | Guggenheim | Michael Schmidt | → $85 | Initiates | → Buy | Get Alert |
| 03/08/2023 | Buy Now | 149.86% | HC Wainwright & Co. | Patrick Trucchio | → $90 | Reiterates | → Buy | Get Alert |
| 02/15/2023 | Buy Now | 99.89% | Oppenheimer | Justin Kim | $65 → $72 | Maintains | Outperform | Get Alert |
| 12/16/2022 | Buy Now | — | Goldman Sachs | Rajan Sharma | — | Upgrade | Neutral → Buy | Get Alert |
| 11/30/2022 | Buy Now | 122.1% | Barclays | Peter Lawson | → $80 | Initiates | → Overweight | Get Alert |
| 11/21/2022 | Buy Now | 149.86% | HC Wainwright & Co. | Patrick Trucchio | $80 → $90 | Maintains | Buy | Get Alert |
| 11/10/2022 | Buy Now | 119.32% | Morgan Stanley | Andrew Galler | $72 → $79 | Maintains | Overweight | Get Alert |
| 10/13/2022 | Buy Now | 99.89% | Morgan Stanley | Andrew Galler | $77 → $72 | Maintains | Overweight | Get Alert |
| 09/14/2022 | Buy Now | 86.01% | JP Morgan | Jessica Fye | $60 → $67 | Maintains | Overweight | Get Alert |
| 09/09/2022 | Buy Now | 113.77% | Morgan Stanley | Andrew Galler | → $77 | Initiates | → Overweight | Get Alert |
| 09/08/2022 | Buy Now | 127.65% | Ladenburg Thalmann | Ahu Demir | → $82 | Initiates | → Buy | Get Alert |
| 08/08/2022 | Buy Now | 94.34% | Cowen & Co. | Tyler Van Buren | → $70 | Initiates | → Outperform | Get Alert |
| 08/02/2022 | Buy Now | 135.98% | BTIG | Justin Zelin | → $85 | Initiates | → Buy | Get Alert |
| 02/08/2022 | Buy Now | 122.1% | HC Wainwright & Co. | Patrick Trucchio | → $80 | Initiates | → Buy | Get Alert |
| 10/20/2021 | Buy Now | 55.47% | Oppenheimer | Justin Kim | — | Initiates | → Outperform | Get Alert |
FAQ
What is the target price for Immunocore Hldgs (IMCR) stock?
The latest price target for Immunocore Hldgs (NASDAQ:IMCR) was reported by HC Wainwright & Co. on June 5, 2024. The analyst firm set a price target for $100.00 expecting IMCR to rise to within 12 months (a possible 177.62% upside). 36 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Immunocore Hldgs (IMCR)?
The latest analyst rating for Immunocore Hldgs (NASDAQ:IMCR) was provided by HC Wainwright & Co., and Immunocore Hldgs reiterated their buy rating.
When was the last upgrade for Immunocore Hldgs (IMCR)?
The last upgrade for Immunocore Holdings PLC happened on December 16, 2022 when Goldman Sachs raised their price target to N/A. Goldman Sachs previously had a neutral for Immunocore Holdings PLC.
When was the last downgrade for Immunocore Hldgs (IMCR)?
There is no last downgrade for Immunocore Hldgs.
When is the next analyst rating going to be posted or updated for Immunocore Hldgs (IMCR)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Immunocore Hldgs, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Immunocore Hldgs was filed on June 5, 2024 so you should expect the next rating to be made available sometime around June 5, 2025.
Is the Analyst Rating Immunocore Hldgs (IMCR) correct?
While ratings are subjective and will change, the latest Immunocore Hldgs (IMCR) rating was a reiterated with a price target of $100.00 to $100.00. The current price Immunocore Hldgs (IMCR) is trading at is $36.02, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.